JP2022549892A5 - - Google Patents

Info

Publication number
JP2022549892A5
JP2022549892A5 JP2022519283A JP2022519283A JP2022549892A5 JP 2022549892 A5 JP2022549892 A5 JP 2022549892A5 JP 2022519283 A JP2022519283 A JP 2022519283A JP 2022519283 A JP2022519283 A JP 2022519283A JP 2022549892 A5 JP2022549892 A5 JP 2022549892A5
Authority
JP
Japan
Application number
JP2022519283A
Other languages
Japanese (ja)
Other versions
JPWO2021058830A5 (https=
JP2022549892A (ja
Filing date
Publication date
Priority claimed from GB201913974A external-priority patent/GB201913974D0/en
Application filed filed Critical
Publication of JP2022549892A publication Critical patent/JP2022549892A/ja
Publication of JP2022549892A5 publication Critical patent/JP2022549892A5/ja
Publication of JPWO2021058830A5 publication Critical patent/JPWO2021058830A5/ja
Pending legal-status Critical Current

Links

JP2022519283A 2019-09-27 2020-09-28 ベクター Pending JP2022549892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913974A GB201913974D0 (en) 2019-09-27 2019-09-27 Vector
GB1913974.0 2019-09-27
PCT/EP2020/077144 WO2021058830A1 (en) 2019-09-27 2020-09-28 Vector

Publications (3)

Publication Number Publication Date
JP2022549892A JP2022549892A (ja) 2022-11-29
JP2022549892A5 true JP2022549892A5 (https=) 2023-10-12
JPWO2021058830A5 JPWO2021058830A5 (https=) 2023-10-12

Family

ID=68538788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519283A Pending JP2022549892A (ja) 2019-09-27 2020-09-28 ベクター

Country Status (8)

Country Link
US (1) US20220380804A1 (https=)
EP (1) EP4034664A1 (https=)
JP (1) JP2022549892A (https=)
CN (3) CN119913208A (https=)
AU (1) AU2020354538A1 (https=)
CA (1) CA3155742A1 (https=)
GB (1) GB201913974D0 (https=)
WO (1) WO2021058830A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3228916A1 (en) * 2021-08-11 2023-02-16 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
CN116064624A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rpl基因促进载体稳定表达的方法及其功能基因
WO2024245120A1 (en) * 2023-05-26 2024-12-05 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating proteinopathies in central nervous system

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP1082413B1 (en) 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav5 vector and uses thereof
CA2349838C (en) 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US7071172B2 (en) * 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
CA2653974A1 (en) * 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
DK2931897T3 (en) * 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
MX2015017312A (es) * 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
EP3245221A4 (en) * 2015-01-16 2018-06-13 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
KR102423442B1 (ko) * 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
WO2017151884A1 (en) * 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia
KR102709597B1 (ko) * 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
IL274926B2 (en) * 2017-12-01 2026-04-01 Encoded Therapeutics Inc Pyrazolopyrimidines with activity against respiratory syncytial virus
KR102171360B1 (ko) * 2018-06-22 2020-10-28 재단법인대구경북과학기술원 사이토카인 융합 폴리펩티드, 및 이를 포함하는 사이토카인 라이브러리
JP2022522995A (ja) * 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Aav粒子を生成するための方法及びシステム
BR112021015817A2 (pt) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
US12595479B2 (en) * 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases

Similar Documents

Publication Publication Date Title
CN305960579S (https=)
CN305534351S (https=)
CN305715345S (https=)
CN305716775S (https=)
CN305717498S (https=)
CN305729179S (https=)
CN305729574S (https=)
CN305730822S (https=)
CN305732110S (https=)
CN305776258S (https=)
CN305776527S (https=)
CN305777824S (https=)
CN305777836S (https=)
CN305781778S (https=)
CN305782943S (https=)
CN305783679S (https=)
CN305785090S (https=)
CN305785434S (https=)
CN305917699S (https=)
CN305920027S (https=)
CN305925158S (https=)
CN305925745S (https=)
CN305928753S (https=)
CN305929129S (https=)
CN305957247S (https=)